COVID-19 and Older Adults: What We Know

Zainab Shahid, Ricci Kalayanamitra, Brendan McClafferty, Douglas Kepko, Devyani Ramgobin, Ravi Patel, Chander Shekher Aggarwal, Ramarao Vunnam, Nitasa Sahu, Dhirisha Bhatt, Kirk Jones, Reshma Golamari, Rohit Jain, Zainab Shahid, Ricci Kalayanamitra, Brendan McClafferty, Douglas Kepko, Devyani Ramgobin, Ravi Patel, Chander Shekher Aggarwal, Ramarao Vunnam, Nitasa Sahu, Dhirisha Bhatt, Kirk Jones, Reshma Golamari, Rohit Jain

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel virus that causes COVID-19 infection, has recently emerged and caused a deadly pandemic. Studies have shown that this virus causes worse outcomes and a higher mortality rate in older adults and those with comorbidities such as hypertension, cardiovascular disease, diabetes, chronic respiratory disease, and chronic kidney disease (CKD). A significant percentage of older American adults have these diseases, putting them at a higher risk of infection. Additionally, many adults with hypertension, diabetes, and CKD are placed on angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers. Studies have shown that these medications upregulate the ACE-2 receptor, the very receptor that the SARS-CoV-2 virus uses to enter host cells. Although it has been hypothesized that this may cause a further increased risk of infection, more studies on the role of these medications in COVID-19 infections are necessary. In this review, we discuss the transmission, symptomatology, and mortality of COVID-19 as they relate to older adults, and possible treatments that are currently under investigation. J Am Geriatr Soc 68:926-929, 2020.

Keywords: COVID-19; SARS-CoV-2; coronavirus; mortality; older adults.

Conflict of interest statement

The authors have declared no conflicts of interest for this article.

© 2020 The American Geriatrics Society.

References

    1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270‐273.
    1. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID‐19) outbreak—an update on the status. Mil Med Res. 2020;7(1):11.
    1. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS‐CoV‐2. Nat Med. 2020; 10.1038/s41591-020-0820-9
    1. Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS‐CoV‐2 associated with the COVID‐19 outbreak. Curr Biol. 2020;30(7):1346‐1351.e2.
    1. Coronavirus Resource Center . Coronavirus COVID‐19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. . Accessed March 26, 2020.
    1. Centers for Disease Control and Prevention . Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID‐19)—United States, February 12–March 16, 2020. . Accessed March 26, 2020.
    1. Adhikari SP, Meng S, Wu YJ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID‐19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29.
    1. Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID‐19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020. 10.7326/M20-0504
    1. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS‐CoV‐2 as compared with SARS‐CoV‐1. N Engl J Med. 2020. 10.1056/NEJMc2004973
    1. Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, Guo Q, Sun X, Zhao D, Shen J, Zhang H, Liu H, Xia H, Tang J, Zhang K, Gong S Characteristics of pediatric SARS‐CoV‐2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020; 10.1038/s41591-020-0817-4
    1. Centers for Disease Control and Prevention (CDC) . National Diabetes Statistics Report 2020. . Accessed March 26, 2020.
    1. Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon‐Moran D. Hypertension prevalence and control among adults: United States, 2015‐2016. NCHS Data Brief. 2017;289:1‐8.
    1. Centers for Disease Control and Prevention . Chronic Kidney Disease in the United States, 2019. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2019.
    1. Zheng YY, Ma YT, Zhang JY, Xie X. COVID‐19 and the cardiovascular system. Nat Rev Cardiol. 2020. 10.1038/s41569-020-0360-5
    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497‐506.
    1. Zhu W, Xie K, Lu H, Xu L, Zhou S, Fang S. Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei, China. J Med Virol. 2020. 10.1002/jmv.25763
    1. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID‐19 in Washington State. JAMA. 2020. 10.1001/jama.2020.4326
    1. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation between chest CT findings and clinical conditions of coronavirus disease (COVID‐19) pneumonia: a multicenter study. AJR Am J Roentgenol. 2020;3:1‐6.
    1. WHO‐China Joint Mission . Report of the WHO‐China Joint Mission on Coronavirus Disease 2019 (COVID‐19). . Accessed March 26, 2020.
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239‐1242. 10.1001/jama.2020.2648
    1. Italian COVID‐19 Surveillance Group . Report sulle caratteristiche dei pazienti deceduti positivi a COVID‐19 in Italia Il presente report è basato sui dati aggiornati al 17 Marzo 2020. . Accessed March 26, 2020.
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054‐1062. 10.1016/S0140-6736(20)30566-3
    1. National Diabetes Statistics Report 2020. . Accessed March 27, 2020.
    1. Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon‐Moran D. Hypertension prevalence and control among adults: United States, 2015‐2016. NCHS Data Brief No. 289. Hyattsville, MD: National Center for Health Statistics; 2017.
    1. CDC . Coronary Heart Disease, Myocardial Infarction, and Stroke—A Public Health Issue. . Accessed March 26, 2020.
    1. CDC . Chronic Obstructive Pulmonary Disease Among Adults—United States, 2011. . Accessed March 26, 2020.
    1. Frieden TR, Lee CT. Identifying and interrupting superspreading events—implications for control of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020;26(6). 10.3201/eid2606.200495
    1. Ong SWX, Tan YK, Chia PY, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) from a symptomatic patient. JAMA. 2020. 10.1001/jama.2020.3227
    1. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246‐251.
    1. Vincent MJ, Bergeron E, Benjannet S. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.
    1. Chinese Clinical Trial Registry. . Accessed March 26, 2020.
    1. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID‐19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72‐73.
    1. Gautret P, Lagier JC, Parola P. Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial. Int J Antimicrob Agents. 2020;20:105949.
    1. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019‐nCoV) in vitro. Cell Res. 2020;30(3):269‐271.
    1. Emergency Access to Remdesivir Outside of Clinical Trials. . Accessed March 26, 2020.
    1. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929‐936.
    1. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS‐5734™) in Participants with Moderate Coronavirus Disease (COVID‐19) Compared to Standard of Care Treatment. . Accessed March 27, 2020.
    1. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS‐5734™) in Participants with Severe Coronavirus Disease (COVID‐19). . Accessed March 27, 2020.
    1. Adaptive COVID‐19 Treatment Trial (ACTT). . Accessed March 26, 2020.
    1. EU Clinical Trials Register. . Accessed March 26, 2020.
    1. Mild/Moderate 2019‐nCoV Remdesivir RCT. . Accessed March 26, 2020.
    1. Severe 2019‐nCoV Remdesivir RCT. . Accessed March 26, 2020.
    1. Safety and Immunogenicity Study of 2019‐nCoV Vaccine (mRNA‐1273) to Prevent SARS‐CoV‐2 Infection. . Accessed March 26, 2020.
    1. Update: Public Health Response to the Coronavirus Disease 2019 Outbreak—United States, February 24, 2020. . Accessed March 26, 2020.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj